Literature DB >> 15195241

Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type.

Anna-Barbara Moscicki1, Jonas H Ellenberg, Sepideh Farhat, Jiahong Xu.   

Abstract

BACKGROUND: High rates of persistence of human papillomavirus (HPV) infection have been reported for adult women with human immunodeficiency virus (HIV) infection. Although most women are first infected with HPV during adolescence, persistence of specific HPV types has not been carefully examined among HIV-infected adolescents. The objective of this study was to examine the rates of and risk factors for persistence of HPV types among HIV-infected and -uninfected adolescent girls.
METHODS: This is a prospective cohort study of female adolescents, aged 13-18 years, participating in the Reaching for Excellence in Adolescent Care and Health project, a national study of HIV-infected and -uninfected adolescents. The main outcome measured was type-specific loss of initial HPV DNA detected. Loss of HPV DNA was defined for the following categories of HPV DNA types: low risk, which included types 6, 11, 42, 44, 54, 40, 13, 32, 62, 72, 2, 57, and 55; and high risk, which included types 16-like (16, 31, 33, 35, 52, 58, and 67), 18-like (18, 39, 45, 59, 68, 70, 26, 69, and 51), and 56-like (56, 53, and 66).
RESULTS: Prevalent or incident HPV infection was detected in 334 girls. When type-specific loss of HPV was examined, HIV-uninfected girls had a shorter mean time to loss of initial infection than did HIV-infected girls (403 days vs. 689 days, respectively; P<.0001). By means of multivariate analysis, CD4 immunosuppression and the presence of multiple HPV-type subgroups were found to be associated with persistence of HPV.
CONCLUSION: Since persistence of high-risk HPV types has been strongly linked with the development of invasive cancer, the prolonged persistence of HPV observed among HIV-infected adolescents who are relatively healthy underscores the importance of prevention of HPV infection in this group.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15195241     DOI: 10.1086/421467

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  85 in total

1.  Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: a prospective cohort.

Authors:  Tanvier Omar; Sheree Schwartz; Colleen Hanrahan; Tebogo Modisenyane; Nkeko Tshabangu; Jonathan E Golub; James A McIntyre; Glenda E Gray; Lerato Mohapi; Neil A Martinson
Journal:  AIDS       Date:  2011-01-02       Impact factor: 4.177

2.  Incidence and Persistence of High-risk Anogenital Human Papillomavirus Infection Among Female Youth With and Without Perinatally Acquired Human Immunodefiency Virus Infection: A 3-year Observational Cohort Study.

Authors:  Nittaya Phanuphak; Sirinya Teeraananchai; Rawiwan Hansudewechakul; Sivaporn Gatechompol; Kulkanya Chokephaibulkit; Hanh Le Dung Dang; Dan Ngoc Hanh Tran; Jullapong Achalapong; Nipat Teeratakulpisarn; Amphan Chalermchockcharoenkit; Manopchai Thamkhantho; Tippawan Pankam; Thida Singtoroj; Wichai Termrungruanglert; Surasith Chaithongwongwatthana; Stephen J Kerr; Annette H Sohn
Journal:  Clin Infect Dis       Date:  2020-11-05       Impact factor: 9.079

3.  Human Papillomavirus Vaccination and Infection in Young Sexual Minority Men: The P18 Cohort Study.

Authors:  Perry N Halkitis; Pamela Valera; Caleb E LoSchiavo; Stephen E Goldstone; Maria Kanztanou; Anthony J Maiolatesi; Danielle C Ompad; Richard E Greene; Farzana Kapadia
Journal:  AIDS Patient Care STDS       Date:  2019-04       Impact factor: 5.078

Review 4.  Human papillomavirus disease and vaccines in adolescents.

Authors:  Anna-Barbara Moscicki
Journal:  Adolesc Med State Art Rev       Date:  2010-08

Review 5.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

Review 6.  Immune therapy for human papillomaviruses-related cancers.

Authors:  Ricardo Rosales; Carlos Rosales
Journal:  World J Clin Oncol       Date:  2014-12-10

7.  Human papillomavirus infections in nonsexually active perinatally HIV infected children.

Authors:  Anna-Barbara Moscicki; Ana Puga; Sepideh Farhat; Yifei Ma
Journal:  AIDS Patient Care STDS       Date:  2014-01-24       Impact factor: 5.078

8.  Type-specific incidence, clearance and predictors of cervical human papillomavirus infections (HPV) among young women: a prospective study in Uganda.

Authors:  Cecily Banura; Sven Sandin; Leen-Jan van Doorn; Wim Quint; Bernhard Kleter; Fred Wabwire-Mangen; Edward K Mbidde; Elisabete Weiderpass
Journal:  Infect Agent Cancer       Date:  2010-04-09       Impact factor: 2.965

9.  Epidemiology of HPV in HIV-positive and HIV-negative fertile women in Cameroon, West Africa.

Authors:  Andrew J Desruisseau; Delf Schmidt-Grimminger; Edith Welty
Journal:  Infect Dis Obstet Gynecol       Date:  2010-02-09

10.  Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa.

Authors:  Cynthia Firnhaber; Hoa Van Le; Audrey Pettifor; Doreen Schulze; Pam Michelow; Ian M Sanne; David A Lewis; Anna-Lise Williamson; Bruce Allan; Sophia Williams; Allen Rinas; Simon Levin; Jennifer S Smith
Journal:  Cancer Causes Control       Date:  2009-12-01       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.